#### Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living 1

#### with HIV: a nationwide prospective cohort study in the Netherlands 2

3	Katł	nryn S. Hensley <sup>1</sup> , Marlou J. Jongkees <sup>1¶</sup> , Daryl Geers <sup>2¶</sup> , Corine H. GeurtsvanKessel <sup>2</sup> , Yvonne M.									
4	Mue	eller <sup>3</sup> , Virgil A.S.H. Dalm <sup>3,4</sup> , Grigorios Papageorgiou <sup>5</sup> , Hanka Steggink <sup>6</sup> , Alicja Gorska <sup>1</sup> , Susanne									
5	Bog	ers <sup>2</sup> , Jan G. den Hollander <sup>7</sup> , Wouter F.W. Bierman <sup>8</sup> , Luc B.S. Gelinck <sup>9</sup> , Emile F. Schippers <sup>10,11</sup> , Heidi									
6	S.M. Ammerlaan <sup>12</sup> , Marc van der Valk <sup>13,14</sup> , Marit G.A. van Vonderen <sup>15</sup> , Corine E. Delsing <sup>16</sup> , Elisabeth H.										
7	Gisolf <sup>17</sup> , Anke H.W. Bruns <sup>18</sup> , Fanny N. Lauw <sup>19</sup> , Marvin A.H. Berrevoets <sup>20</sup> , Kim C.E. Sigaloff <sup>21</sup> , Robert										
8	Soe	tekouw <sup>22</sup> , Judith Branger <sup>23</sup> , Quirijn de Mast <sup>24</sup> , Adriana J.J. Lammers <sup>25</sup> , Selwyn H. Lowe <sup>26</sup> , Rory D. de									
9	Vrie	s <sup>2</sup> , Peter D. Katsikis <sup>3</sup> , Bart J.A. Rijnders <sup>1</sup> , Kees Brinkman <sup>6</sup> , Anna H.E. Roukens <sup>11&amp;</sup> , Casper Rokx <sup>1&amp;*</sup>									
10	1.	Department of Internal Medicine, Section Infectious Diseases, and Department of Medical									
11		Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam									
12	2.	Department of Viroscience, Erasmus University Medical Centre, Rotterdam									
13	3.	Department of Immunology, Erasmus University Medical Centre, Rotterdam									
14	4.	Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University									
15		Medical Centre, Rotterdam									
16	5.	Department of Biostatistics, Erasmus University Medical Centre, Rotterdam									
17	6.	Department of Internal Medicine and Infectious Diseases, OLVG Hospital, Amsterdam									
18	7.	Department of Internal Medicine, Maasstad Hospital, Rotterdam									
19	8.	Department of Internal Medicine, Section Infectious Diseases, University of Groningen, Groningen									
20	9.	Department of Internal Medicine and Infectious Diseases, Haaglanden Medical Centre, The Hague									
21	10.	Department of Internal Medicine, Haga Teaching Hospital, The Hague									
22	11.	Department of Infectious Diseases, Leiden University Medical Centre, Leiden									
23	12.	Department of Internal Medicine, Catharina Hospital, Eindhoven									
24	13.	Department of Internal Medicine and Infectious Diseases, DC Klinieken, Amsterdam									

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25	14.	Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam
26		University Medical Centres, University of Amsterdam, Amsterdam
27	15.	Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden
28	16.	Department of Internal Medicine and Infectious Diseases, Medisch Spectrum Twente, Enschede
29	17.	Department of Internal Medicine and Infectious Diseases, Rijnstate Hospital, Arnhem
30	18.	Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht,
31		Utrecht
32	19.	Department of Internal Medicine and Infectious Diseases, Medical Centre Jan van Goyen,
33		Amsterdam
34	20.	Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg
35	21.	Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Infection &
36		Immunity Institute, Amsterdam UMC, VU University, Amsterdam
37	22.	Department of Internal Medicine and Infectious Diseases, Spaarne Gasthuis, Haarlem
38	23.	Department of Internal Medicine, Flevo Hospital, Almere
39	24.	Department of Internal Medicine, Radboud Centre for Infectious Diseases, Radboud University
40		Medical Centre, Nijmegen
41	25.	Department of Internal Medicine and Infectious Diseases, Isala Hospital, Zwolle
42	26.	Department of Internal Medicine and Infectious Diseases, Maastricht University Medical Centre,
43		Maastricht
44	All i	n the Netherlands
45	* Co	prresponding author
46	Dr.	C. Rokx, c.rokx@erasmusmc.nl (C)
47		
48	¶Th	ese authors contributed equally to this work.
49	& TI	nese authors also contributed equally to this work.

### 51 Abstract

### 52 Background

Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations
this is unknown.

### 55 Methods and Findings

A prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S and Ad26.COV2.S vaccines in adult PLWH, without prior COVID-19, compared to HIV-negative controls. The primary endpoint was the anti-spike SARS-CoV-2 IgG response after mRNA vaccination. Secondary endpoints included the serological response after vector vaccination, anti-SARS-CoV-2 T-cell response and reactogenicity.

61 Between February-September 2021, 1154 PLWH (median age 53 [IQR 44-60], 86% male) and 440 controls (median age 43 [IQR 33-53], 29% male) were included. 884 PLWH received BNT162b2, 100 62 63 mRNA-1273, 150 ChAdOx1-S, and 20 Ad26.COV2.S. 99% were on antiretroviral therapy, 98% virally 64 suppressed, and the median CD4+T-cell count was 710 cells/µL [IQR 520-913]. 247 controls received mRNA-1273, 94 BNT162b2, 26 ChAdOx1-S and 73 Ad26.COV2.S. After mRNA vaccination, geometric 65 66 mean concentration was 1418 BAU/mL in PLWH (95%CI 1322-1523), and after adjustment for age, sex, and vaccine type, HIV-status remained associated with a decreased response (0.607, 95%CI 67 68 0.508-0.725). In PLWH vaccinated with mRNA-based vaccines, higher antibody responses were 69 predicted by CD4+T-cell counts 250-500 cells/µL (2.845, 95%CI 1.876-4.314) or >500 cells/µL (2.936, 70 95%CI 1.961-4.394), whilst a viral load >50 copies/mL was associated with a reduced response 71 (0.454, 95%CI 0.286-0.720). Increased IFN-y, CD4+, and CD8+T-cell responses were observed after 72 stimulation with SARS-CoV-2 spike peptides in ELISpot and activation induced marker assays, 73 comparable to controls. Reactogenicity was generally mild without vaccine-related SAE.

# 74 Conclusion

- 75 After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced
- in PLWH. To reach and maintain the same serological responses and vaccine efficacy as HIV-negative
- 77 controls, additional vaccinations are probably required.
- 78 Keywords: SARS-CoV-2 vaccines; HIV infection; COVID-19; COVID-19 vaccination; PLWH; BNT162b2;
- 79 *mRNA-1273; ChAdOx1-S; Ad26.COV2.S*

# 81 Introduction

At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged and the ensuing and ongoing pandemic led to the loss of millions of lives. Highly effective vaccines were quickly implemented, and mass vaccination campaigns have become the cornerstone to prevent fatal Coronavirus Disease (COVID-19) to quell this pandemic, four of which are currently approved for use in the Netherlands [1-5].

After the SARS-CoV-2 vaccine registration trials, vaccinations were rolled out globally. However, people with immune deficiencies were only sporadically included in the original phase three SARS-CoV-2 vaccination trials. Subsequent reports indicated markedly diminished responses in solid organ transplant recipients, and lower responses in haemodialysis patients, stem cell recipients or patient groups on specific immunosuppressant drugs for immune disorders [6-9].

92 HIV infection is associated with worse COVID-19 outcomes although the underlying mechanism is not 93 yet clear [10]. In most countries, people living with HIV (PLWH) were therefore prioritised for SARS-94 CoV-2 vaccination. PLWH show diminished responses to a wide variety of vaccines such as hepatitis B, 95 and seasonal influenza vaccines compared to HIV-uninfected individuals [11, 12]. This might also hold 96 true for SARS-CoV-2 vaccines. Indicative of potential lower responses to SARS-CoV-2 vaccines could be 97 that after SARS-CoV-2 infection, lower IgG concentrations and neutralising antibody titres were found 98 in PLWH compared to controls [13]. Data are scarce on SARS-CoV-2 vaccination responses in PLWH. 99 Small studies using the ChAdOx1-S vaccine in the UK and South Africa in relatively young PLWH with 100 high CD4+ T-cell counts gave comparable responses to controls [14, 15]. As for BNT162b2, similar 101 results were shown in a limited number of PLWH [16-18]. The identification of risk factors for a reduced 102 response to SARS-CoV-2 vaccines in PLWH is important as it will help to improve vaccination strategies 103 in PLWH. A good understanding of vaccination response in PLWH becomes even more important now 104 that variants of concern (VOC) continue to arise and partially escape vaccine induced immunity [19].

- 105 In this study we investigated the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in
- 106 PLWH with the vaccines currently approved in the Netherlands; BNT162b2, mRNA-1273, ChAdOx1-S,
- 107 or Ad26.COV2.S.

## 109 Methods

### 110 Study design and participants

- We performed a prospective observational cohort study in 22 of the 24 HIV treatment centres in the Netherlands. Participants were recruited via treating physicians or nurses specialised in HIV-care. To be eligible for participation, a subject had to be 18 years or older, had a confirmed HIV infection and was invited for SARS-CoV-2 vaccination by Dutch public health services. Participants with a history of previous SARS-CoV-2 infection demonstrated by PCR or detectable SARS-CoV-2 antibodies in serum before vaccination were excluded. Inclusion was stratified and monitored to best represent represents the Dutch population of PLWH (S1 appendix) [20].
- Participants received either BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S according to
  manufacturer's regulations as part of the Dutch SARS-CoV-2 vaccination campaign (S1 appendix).
  Vaccination response data from HIV-negative controls were obtained from two separate concurrent
  studies (n=440; S1 appendix) [21].

### 122 Clinical procedures

Blood samples were collected up to six weeks before vaccination (T0) and four to six weeks after the completed vaccination schedule (T2). In a subgroup, additional blood samples were collected, 21 days (+/- three days) after the first vaccination for serology (T1) or peripheral blood mononuclear cells (PBMCs) at any of the study visits. Participants are scheduled for longitudinal blood sampling for additional analyses during two years which will be reported separately.

Study variables were collected in an electronic case record file (S1 appendix). Participants received a paper diary or a link to an online questionnaire to enter adverse events (AE) from a predefined list and medication use for AE the seven days following each vaccination.

### 131 Laboratory procedures

All serum samples were collected via venepuncture at participating centres. Serum samples before vaccination were analysed at the laboratory of the individual treating centres with the available SARS-CoV-2 antibody test (S1 appendix) . Serum samples post-vaccination were transported for testing at the department of Viroscience, Erasmus Medical Centre, the Netherlands. The presence of binding antibodies against the SARS-CoV-2 Spike (S1) were quantified with a validated IgG Trimeric chemiluminescence immunoassay (DiaSorin Liaison) with a lower limit of detection at 4.81 binding antibody units per millilitre (BAU/mL).

PBMCs were isolated by density gradient centrifugation (Ficoll-Hypaque, GE Healthcare life sciences)
and collected in RPMI-1640 (Life Technologies) supplemented with 3% foetal bovine serum (FBS).
PBMCs were washed three times, frozen in freezing media (90% FBS, 10% dimethyl sulfoxide (DMSO))
and stored in liquid nitrogen until use.

We used enzyme linked immune absorbent spots (ELISpot) to quantify interferon (IFN)-γ secretion in
 response to SARS-CoV-2 peptides. ELISpot assays were performed on cryopreserved PBMCs using a
 commercial double colour kit (ImmunoSpot®, Cellular Technology Limited) including peptide pools
 containing spike and nucleocapsid protein (S1 appendix). Results are expressed as spot forming cells
 (SFCs) per million PBMCs, calculated by subtracting mean response after MOG stimulation.

T-cell responses were further characterised by activation induced marker (AIM) assay. PBMCs were incubated with SARS-CoV-2 peptide pools covering the entire S-protein of the WuhanHu1 (wild-type) or B.1.617.2 (delta) variant. Following stimulation, cells were stained and measured by flow cytometry (FACSLyric, BD; S1 appendix). SARS-CoV-2-reactive T-cells were identified as CD137+OX40+ for CD4+ subtype or CD137+CD69+ for CD8+ subtype. On average, 300,000 cells were measured. The gating strategy can be found in S1 Fig.

### 154 Outcomes

155 The primary outcome was the height of the anti-spike SARS-CoV-2 IgG response in PLWH 4-6 weeks 156 after the completed vaccination schedule with BNT162b2 or mRNA-1273. This endpoint was chosen 157 because primarily mRNA vaccines were allocated to PLWH in the Netherlands. Secondary outcomes 158 included the antibody response in PLWH after the completed vaccination schedule with ChAdOx1-S 159 and Ad26.COV2.S, and variables associated with the height of antibody level (S1 appendix). Variables 160 associated with hyporesponse and non-response were also analysed (S1 appendix). We defined a 161 hyporesponse as 50-300 BAU/mL and non-response as <50 BAU/mL, based on previous studies which 162 showed correlation of antibody concentration of 300 BAU/mL with a neutralising capacity of 1:40.[9, 22] In the subgroup, anti-spike SARS-CoV-2 specific T-cell response, and antibody response 21 days 163 after the first vaccine dose were evaluated. Lastly, we evaluated the tolerability of the vaccines by 164 165 monitoring vaccine-related AE (S1 appendix).

### 166 Sample size and statistical analysis plan

167 When the study started, we did not have a confirmed availability of a control group due to the rapid 168 initiation of the national immunisation campaign. We justified the sample size by calculating that 556 169 PLWH receiving mRNA vaccines would be sufficient to detect a serological response rate of 90% or 170 lower compared to a hypothetical 95% response rate in controls with >80% power. When the control 171 group was confirmed, and before the data lock and endpoint analyses, we amended the protocol to 172 update the sample size calculation. Accounting for the imbalance in the number of controls versus 173 PLWH with BNT162b2 and mRNA-1273 vaccinations, we found that 286 controls were sufficient to 174 detect a 20% lower antibody response in PLWH with >80% power and alpha 5%.

175 Median (interquartile range (IQR)), or n (%) for descriptive data were used. A multivariable linear 176 regression model was used for the analysis of the anti-spike SARS-CoV-2 IgG. The outcome was 177 transformed using the natural logarithm plus one unit: ln(anti-spike SARS-CoV-2 IgG+1) in order to

178 meet the model assumptions. All patients of which the sample was received in the central laboratory 179 for testing who completed the vaccination scheme were included in the analysis (per protocol). The 180 difference between PLWH and controls was captured by the corresponding regression coefficient and 181 95%CI. The model was further adjusted for differences in vaccine type, age, and sex. A multivariable 182 linear regression model was also used to quantify the difference in In(anti-spike SARS-CoV-2 IgG+1) 183 between PLWH versus controls for the subset in the sample vaccinated with vector vaccines. A similar model was used to quantify the effect of age, sex, vaccine type, most recent CD4+ T-cell count, and 184 185 antibody concentration in PLWH. In addition, multivariable logistic regression models were used to 186 calculate odds ratios with 95%Cl for the effects of sex, age, nadir CD4+ T-cell count, most recent CD4+ 187 T-cell count, HIV-RNA viral load, and vaccine group in PLWH on having a hyporesponse or a non-188 response. In subgroup participants we evaluated differences from baseline to T1 and T1 to T2, as well 189 as AIM data comparing T0 and T2 time points, by Wilcoxon matched-pairs signed rank test. ELISpot T0 190 to T2 data and AIM data comparing PLWH and controls were analysed by Mann-Whitney-U tests.

Data were analysed using IBM SPSS Statistics 25, R (v. 4.1.2), and GraphPad Prism 8. Flow cytometry
data were analysed using FlowJo software version 10.8.1.

### 193 Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation,or writing of the report.

### 196 **Ethical considerations**

197 The trial was performed in accordance with the principles of the Declaration of Helsinki, Good Clinical 198 Practice guidelines, and in accordance with the Dutch Medical Research Involving Human Subjects Act 199 (WMO). Written informed consent was obtained from all participants. The trial was reviewed and 200 approved by the Medical research Ethics Committees United Nieuwegein (MEC-U, reference 20.125). 201 The trial was registered in the Netherlands Trial Register (NL9214).

### 202 **Results**

### **Baseline characteristics**

204 Between 14 February and 7 September 2021, 1269 PLWH were enrolled (Fig 1.). At sampling before 205 vaccination, 53 (4.2%) PLWH had antibodies against SARS-CoV-2 above test cut-off and were excluded. 206 Overall, 30 PLWH were lost to follow-up (2.4%), five decided against vaccination after inclusion (0.4%), 207 eight withdrew from the study (0.6%), and ten samples were not stored adequately or not received in 208 the central laboratory for testing (0.8%). One participant was excluded from the final analysis because 209 they received two different vaccines (ChAdox1-S and BNT162b2). In the final analysis, 76.6% PLWH 210 received BNT162b2, 8.7% mRNA-1273, 13.0% ChAdOx1-S and 1.7% Ad26.COV2.S. Included PLWH had 211 a median age of 53 [IQR 44-60], 85.5% were men and had a median CD4+ T-cell count before 212 vaccination of 710 cells/µL [IQR 520-913] (Table 1). The vast majority (99.0%) was on cART and had a 213 suppressed plasma HIV-RNA (97.7% <50 copies/mL). The control group consisted of 440 people of 214 which 94 were vaccinated with BNT162b2 (21.4%), 247 with mRNA-1273 (56.1%), 26 ChAdOx1-S (5.9%) 215 and 73 Ad26.COV2.S (16.6%). Their median age was 43 [IQR 33-53] and 28.6% were men. The age 216 distribution across groups differed, with the majority of PLWH receiving ChAdOx1-S being 55-65 years 217 of age compared to 15-25% for the other vaccines (S1 Table). Age differences were also seen between 218 groups, with less participants of older ages in the control group. Between the control group and PLWH, 219 there was also a difference in inclusion of sex. All other factors were similar across groups. In the 220 subgroup of PLWH, baseline characteristics reflected the characteristics of included PLWH, with most 221 participants receiving the BNT162b2 vaccine (66.0-95.3%) and being male (76.6-85.7%) (S2 Table).

Fig 1. Flow chart of inclusions of PLWH \*Participants that tested positive for SARS-CoV-2 antibodies in serum at baseline measurement were excluded from further participation +Samples were not stored adequately or sent to be analysed in the central laboratory at the Erasmus MC ++ One participant received a combination ChAdOx1-S and BNT162b2 vaccines and was therefore not included in the per protocol analysis. PLWH: people living with HIV



#### 229 Table 1: Baseline characteristics of HIV negative controls and PLWH.

	HIV negative participants			People living with HIV			
	Overall	mRNA	Vector	Overall	mRNA	Vector	
	N = 440	vaccines <sup>1</sup>	vaccines <sup>2</sup>	N = 1154	vaccines <sup>1</sup>	vaccines <sup>2</sup>	
		N = 341	N = 99		N = 984	N = 170	
		(77.5%)	(22.5%)		(85.3%)	(14.7%)	
Sex assigned at birth					I	I	
Male	126 (28.6%)	104 (30.5%)	22 (22.2%)	987 (85.5%)	839 (85.2%)	148 (87.1%)	
Female	314 (71.4%)	237 (69.5%)	77 (77.8%)	167 (14.5%)	145 (14.8%)	22 (12.9%)	
Age category							
18-55 years	352 (80.0%)	284 (83.3%)	68 (68.7%)	703 (60.9%)	674 (68.5%)	29 (17.1%)	
56-65 years	74 (16.8)	43 (12.6%)	31 (31.3%)	291 (25.2%)	157 (16.0%)	134 (79.3%)	
65+ years	14 (3.2%)	14 (4.1%)	0	160 (13.9%)	153 (15.6%)	7 (4.1%)	
On cART							
Yes	NA	NA	NA	1142 (99.0%)	972 (98.8%)	170 (100%)	
No	NA	NA	NA	12 (1.0%)	12 (1.2%)	0	
Most recent plasma H	V viral load						
<50 copies/mL	NA	NA	NA	1127 (97.7%)	960 (97.6%)	167 (98.2%)	
≥50 copies/mL	NA	NA	NA	27 (2.3%)	24 (2.4%)	3 (1.8%)	
Most recent CD4+ T-ce	ll count			·			
<250 cells/µL	NA	NA	NA	41 (3.6%)	35 (3.6%)	6 (3.5%)	
250-500 cells/μL	NA	NA	NA	224 (19.4%)	189 (19.2%)	35 (20.6%)	
>500 cells/µL	NA	NA	NA	889 (77.0%)	760 (77.2%)	129 (75.9%)	
Nadir CD4+ T-cell coun	t						
<250 cells/µL	NA	NA	NA	443 (38.4%)	365 (37.1%)	78 (45.9%)	
250-500 cells/µL	NA	NA	NA	376 (32.6%)	330 (33.5%)	46 (27.1%)	
>500 cells/µL	NA	NA	NA	152 (13.2%)	133 (13.5%)	19 (11.2%)	
Unknown	NA	NA	NA	183 (15.9%)	156 (15.9%)	27 (15.9%)	
Days between	28 (25-28)	28 (25-28)	56 (56-70)	35 (35-36)	35 (35-36)	70 (49-77)	
doses*							

230 Data are n (%) or median (IQR). 1BNT162b2, mRNA-1273. 2ChAdOx1-S, Ad26.COV2.S \*Does not apply

231 for Ad26.COV2.S. NA: not applicable, PLWH: people living with HIV, IQR: interquartile range, cART:

combination antiretroviral therapy 232

### 233 Humoral responses

234 In all vaccines investigated, antibody concentrations were lower in PLWH compared to controls (Fig 2). 235 In participants vaccinated with an mRNA vaccine, the geometric mean concentration (GMC) was 1418 236 BAU/mL in PLWH (95%CI 1322-1523) and 3560 BAU/mL in controls (95%CI 3301-3840). With regard to 237 the primary endpoint, after adjusting for age, vaccine, and sex, HIV infection remained associated with 238 a 39.35% lower antibody concentration in PLWH compared to controls receiving an mRNA vaccine 239 (0.607, 95%CI 0.508-0.725). The estimated effect of having an HIV infection was larger than the 240 estimated effects of male sex (23.05% (0.769 95%CI 0.667-0.888)) or age >65 years (35.47% (0.645 241 95%CI 0.544-0.765)), which were all significantly associated with a worse vaccine response (p<0.001 242 for all). concentration 243 Fig 2: Antibody PLWH in and controls after vaccination Anti-spike SARS-CoV-2 binding antibodies after BNT162b2, mRNA-1273, ChAdOx1-S or Ads26.COV2.S 244

vaccination in PLWH and HIV-negative control group. The horizontal bar shows the geometric mean
concentration, also indicated above the graphs, with error bars showing geometric standard deviation.
The dotted lines show the lower limit of detection of the performed test (4.81 BAU/mL), non-response
cut-off (50 BAU/mL) and hyporesponse cut-off (300 BAU/mL). S: spike, BAU/mL: binding antibodies per
millilitre, PLWH: people living with HIV, LLOD: lower limit of detection





250

251 Regarding factors possibly related to antibody responses in PLWH who received mRNA vaccines, 252 receiving mRNA-1273 was associated with a 57.15% higher response (1.572, 95%CI 1.225-2.018, 253 p<0.001). Male sex (0.693 95%CI 0.555-0.865, p=0.001) and age over 65 years (0.654 95%CI 0.526-254 0.814, p<0.001) were associated with lower responses of 30.72%, and 34.56% respectively. We found 255 no association between nadir CD4+ T-cell count and antibody responses, but found a significant effect of 54.62% lower antibodies when the HIV-RNA level was over 50 copies/mL (0.454, 95%CI 0.286-0.720, 256 257 p=0.001). The largest effect on antibody levels was associated with current CD4+ T-cell counts between 258 250 and 500 cells/µL (2.845 95%CI 1.876-4.314) and over 500 cells/µL (2.936 95%CI 1.961-4.394) (both 259 p<0.001) with increased antibody concentrations of 184.34% and 193.59% respectively.

260 In participants receiving vector vaccines, after adjustment, HIV was significantly associated with a 261 39.47% lower antibody response, comparable to that in mRNA vaccines (0.605 95%CI 0.387-0.945, 262 p=0.027). Within this group of PLWH receiving vector vaccines, unlike mRNA vaccines, age, sex, and a 263 detectable viral load were not associated with antibody responses, but receiving Ad26.COV2.S was

associated with a 87.67% lower response (0.123 95%Cl 0.051-0.300, p<0.001) and a recent CD4+ T-cell

 $\label{eq:count} 265 \qquad \mbox{count of } 250 \mbox{ to } 500 \mbox{ or over } 500 \mbox{ cells} / \mu L \mbox{ were associated with better responses (both p<0.001)}.$ 

266 Hyporesponse and nonresponse percentages were lower for every vaccine group in PLWH compared 267 to controls (S1 Table). In PLWH, after adjustment, receiving a vector vaccine (p<0.001, OR 0.036), age 268 over 65 (p<0.001, OR 0.282) and a viral load over 50 copies/mL (p=0.017, OR 0.266) were associated 269 with an antibody response under 300 BAU/mL. Most recent CD4+ T-cell count between 250 and 500 270 cells/ $\mu$ L or over 500 cells/ $\mu$ L were significantly associated with an antibody response of 300 BAU/mL 271 or higher (both p<0.001 OR 8.143 and 9.177 respectively). Sex and nadir CD4+ T-cell count were not 272 associated. When looking at non-response in PLWH, receiving a vector vaccine (p<0.001, OR 0.034) 273 was associated with an antibody response <50 BAU/mL. Being 56 to 65 years of age (p=0.025, OR 274 2.919) and most recent CD4+ T-cell count between 250 and 500 cells/ $\mu$ L or over 500 cells/ $\mu$ L (both 275 p<0.001 OR 7.810 and 15.853 respectively) were significantly associated with an antibody response of 276 more than 50 BAU/mL. Sex, viral load and nadir CD4+ T-cell count were not associated.

In the subgroup of PLWH in whom extra sampling was performed 21 days after the first vaccination
(n=43, 95.3% with BNT162b2), we found response rates of 83.3% with a GMC of 148 BAU/ml at T1 and
1952 BAU/mL at T2 (S2 Fig).

### 280 Cellular responses

In the ELISpot assay, spike-specific T-cell responses measured as IFN-γ, after deduction of MOG, increased from a median of 27.5 SFCs per million PBMCs before vaccination to 152.5 SFC postvaccination (p=0.0023) (Fig 3A). In PLWH, stimulating PBMC with the negative control peptide pool MOG already induced a IFN-γ-response, resulting in high background (S3 Fig). No responses in nucleocapsid were seen after subtraction of MOG. Additionally, CD4+ and CD8+ T-cell responses were assessed in an AIM assay. SARS-CoV-2 specific CD4+ T-cell (CD137+OX40+) and CD8+ T-cell responses (CD137+CD69+) both increased compared to baseline following vaccination and after correction for

- 288 DMSO (p=0.0049 and p=0.0078 respectively) (Fig 3C and 3D). CD4+ and CD8+ T cell responses in PLWH
- against the delta variant were similar before and after vaccination. Importantly, both CD4+ and CD8+
- 290 T-cell responses were of similar magnitude between PLWH and HIV negative individuals.

#### 291 Fig 3: Cellular immune responses against SARS-CoV-2 in subgroup participants (PLWH)

- 292 A Cellular immune response to wild type spike by ELISpot assay (T0 n=23, T2 n=45), IFN-γ SFC after
- subtraction of MOG. Statistics performed using Mann Whitney test p=0.0023
- 294 B Cellular immune response to wild type and delta spike in AIM assay (n=14), percentage of CD4+
- 295 CD137+ OX40+ T-cells after subtraction of DMSO. Dotted line shows the LLoD at 0.001%. Statistics
- between T0 and T2 WT in PLWH performed using Wilcoxon matched-pairs sign rank test (p=0.0049),
- 297 T0 and T2 delta: ns. Statistics between PLWH and controls with Mann Whitney test: ns.
- 298 C Cellular immune response to wild type and delta spike in AIM assay (n=14), percentage of CD8+
- 299 CD137+ CD69+ T-cells after subtraction of DMSO. Dotted line shows the LLoD at 0.001%. Statistics
- 300 performed using Wilcoxon matched-pairs sign rank test (p=0.0078), T0 and T2 delta: ns. Statistics
- 301 between PLWH and controls with Mann Whitney test: ns.
- 302 Green circles: mRNA vaccines, Blue squares: vector based vaccines. T0: before vaccination, T2: 4-6
- 303 weeks after second vaccination, PLWH: people living with HIV, IFN: interferon, SFC: spot forming cells,
- 304 PBMCs: peripheral blood mononuclear cells, MOG: myelin- oligodendrocyte glycoprotein, ELISPot:
- 305 enzyme-linked immune absorbent spot, AIM: activation induced marker, DMSO: dimethyl sulfoxide,
- 306 WT: wildtype, ns: not significant LLoD: lower limit of detection

Α













# 308 Reactogenicity

309	In PLWH, the questionnaire was completed 1039 (90.0%) times after the first vaccination and 1026
310	(90.4%) after the second vaccination. Overall, more than half (52.4%) of the participants reported
311	any AE (Table 2). For those who received two dosages, the frequency of AE did not increase after the
312	second vaccination (from 55.2% to 49.6% respectively). AE after first and second vaccination were for
313	BNT162b2 55.2% and 48.0%, mRNA-1273 62.2% and 70.1%, ChAdOx1-S 51.8% and 46.0%, and after
314	the single Ad26.COV2.S vaccination 47.4%. The most commonly reported local reaction was pain at
315	the injection site (44.4%). The most common systemic reactions were myalgia (13.0%) and headache
316	(18.3%). When AE occurred, most were mild 1159 (65.2%) or moderate 523 (29.4%) in severity and
317	self-limiting (Fig 4). Analgesic or antipyretic drug use was necessary in 346 (16.8%) of all participants,
318	for a cumulative 769 AE, of which 400 (52.0%) were moderate and 57 (7.4%) severe AE. Paracetamol
319	(81.2%) was most commonly used. Ten SAE were reported and all considered unrelated. One
320	participant visited the emergency department three days after vaccination with pain in the arm and
321	chest and shortness of breath in whom a pulmonary embolism was excluded and symptoms
322	resolved. Two participants were admitted for a chronic obstructive pulmonary disease exacerbation.
323	The seven other SAE were elective heart surgery, intestinal perforation after infection,
324	Campylobacter jejuni infection, bicycle accident, pyloric stenosis, a hip fracture after a fall and one
325	person died due to a cardiac arrest. There was no discontinuation of the vaccination series due to
326	vaccine related AE.

#### 328 Table 2: Reactogenicity in PLWH.

Adverse event	Overall	BNT162b2		mRNA-1273		ChAdOx1-S		Ad26.COV2.S
	N=2065	N=1593 (	77.1%)	N=177 (8	177 (8.6%) N=276 (13.4%)		3.4%)	N=19 (0.9%)
		1 <sup>st</sup> dose	2 <sup>nd</sup>	1 <sup>st</sup> dose	2 <sup>nd</sup>	1 <sup>st</sup> dose	2 <sup>nd</sup>	
		791	dose	90	dose	139	dose	
		(49.7%)	802	(50.8%)	87	(50.4%)	137	
			(50.3%)		(49.2		(49.6%)	
Any AE	1083	437	358	56	61	72	63	9 (47.4%)
	(52.4%)	(55.2%)	(48.0%)	(62.2%)	(70.1%)	(51.8%)	(46.0%)	
Local AE					I.	ı	ı	L
Pain at the	917	393	325	52	57	51	32	7 (36.8%)
injection site	(44.4%)	(49.7%)	(40.5%)	(57.8%)	(65.5%)	(36.7%)	(23.4%)	
Redness at the	83	27	29	5	7	7 (5.0%)	8 (5.8%)	0
injection site	(4.0%)	(3.4%)	(3.6%)	(5.6%)	(8.0%)			
Systemic AE						I	I	I
Generalised	269	84	107	15	26	21	13	3 (15.8%)
myalgia	(13.0%)	(10.6%)	(13.3%)	(16.7%)	(29.9%)	(15.1%)	(9.5%)	
Fever	72	14	26	4	15	8 (5.8%)	5 (3.6%)	0
	(3.5%)	(1.8%)	(3.2%)	(4.4%)	(17.2%)			
Headache	377	126	134	20	28	41	24	4 (21.1%)
	(18.3%)	(15.9%)	(16.7%)	(22.2%)	(32.2%)	(29.5%)	(17.5%)	
Rash other	19	12	2 (0.2%)	1	3	0	0	1 (5.3%)
than injection	(0.9%)	(1.5%)		(1.1%)	(3.4%)			
site								
Lymph-	41	13	18	2	5	0	3 (2.2%)	0
adenopathy	(2.0%)	(1.6%)	(2.2%)	(2.2%)	(5.7%)			
Medication use								
Any	346	116	120	19	26	34	23	2 (10.5%)
medication	(16.8%)	(14.7%)	(15.0%)	(21.1%)	(29.9%)	(24.5%)	(16.8%)	
Paracetamol	281	95	97	16	22	30	21	2 (100%)
	(81.2%)	(81.9%)	(80.8%)	(84.2%)	(84.6%)	(88.2%)	(91.3%)	
NSAID	34	13	13	3	4	2 (5.9%)	1 (4.3%)	0
	(9.8%)	(11.2%)	(10.8%)	(15.8%)	(15.4%)			
Other	31	8 (6.9%)	10	0	0	2 (5.9%)	1 (4.3%)	0
	(9.0%)		(8.3%)					

- 329 Reactogenicity after vaccine administration occurring within seven days after each dose in PLWH.
- 330 Data are n (%)\*Does not apply for Ad26.COV2.S. AE: adverse events, NSAID: non-steroidal anti-
- 331 inflammatory drug, PLWH: people living with HIV
- 332
- 333 Fig 4: Severity of adverse events
- 334 Severity of AE present in the seven days after vaccination in PLWH comparing mRNA (BNT162b2,
- mRNA-1273) and vector (ChAdOx1-S, Ad26.COV2.S) vaccines shown as a percentage (%).
- 336 AE: adverse events, PLWH: people living with HIV



337

# 339 Conclusion

Limited data exist on SARS-CoV-2 vaccination responses in PLWH. Here, we show that mRNA induces lower SARS-CoV-2 S1-specific IgG levels in PLWH compared to controls, even after correction for age, sex, and vaccine type. PLWH receiving a vector vaccine, of an older age, and with lower CD4+ T-cell counts have more impaired antibody responses. As expected, the SARS-CoV-2 vaccines were well tolerated in PLWH without vaccine related discontinuations or SAE.

345 Our primary result analysis in participants receiving mRNA vaccines contrasts with most of the small 346 cohort studies performed in PLWH where the authors found similar responses as in controls [16-18]. 347 With regard to vector vaccines in our study, similar effects were seen as for mRNA vaccines, with lower 348 antibody concentrations in PLWH compared to controls. This differs from previously published results on ChAdOx1-S where no differences were seen between PLWH and HIV-negative participants [14, 15]. 349 350 Most, if not all, of the previous studies had not been powered to detect a predefined size of the impact 351 of HIV on vaccination response. Therefore, this discrepancy is probably a type two error of the previous 352 much smaller studies. Other reasons that may explain why some of the previous studies did not find a 353 lower response in PLWH may be the use of qualitative rather than quantitative antibody responses 354 and the inclusion of younger and more female participants. In contrast to the phase three trials, we 355 observed a lower response in male participants [1, 2]. However, this was observed in other vaccination 356 studies in PLWH previously [23]. Additionally, age is also known to influence the immune response to 357 SARS-CoV-2. Our results confirm this in PLWH, in whom more immunosenescence is seen compared 358 to HIV-negative controls [24, 25].

Overall, we found an increase in T-cell responses both on activation of CD4+ and CD8+ T-cells, and cytokine production when exposed to SARS-CoV-2 spike protein. There were still a relevant proportion of PLWH in whom T-cell responses after stimulation could not be measured. However, in the AIM assay this was also observed in controls. Low-response or non-response has also been seen in ELISPOT assays performed previously on healthy participants after vaccination [26]. We observed a relevant IFN-y

production in the negative control stimulation in the PLWH group. Chronic immune activation and persistent inflammation has been reported before in chronic HIV patients, and could explain these results [27].

Adverse events occurred in just over half of all cases. When looking at BNT162b2, the overall incidence of AE did not increase after the second vaccination although the type of AE differed somewhat (e.g. systemic events occurred more often after the second). Overall, AE patterns in PLWH were mild and similar to phase three trials, both in type and frequency [1-3, 5].

This study was performed at 22 of total 24 HIV treatment sites in the Netherlands. Our recruitment strategy resulted in a large group of PLWH, with reasonable representation of female, as well as elderly and those with lower CD4+ T-cell count. This reflected the HIV demographic in the Netherlands, in which the 90-90-90 goals were already reached in 2018 [28].

Several limitations are noteworthy. Because provision of vaccinations was decided by the Dutch National Institute for Public Health and the Environment, we could not fully control the distribution of the available vaccines across age, sex, and CD4+ T-cell strata. Furthermore, there were some differences in age and sex between the PLWH and controls, which we corrected for in our multivariate analyses. We can also not fully guarantee that all participants with an antecedent COVID-19 infection were excluded as antibodies may become undetectable over time. Finally, few PLWH with a very low CD4+ T-cell count were enrolled and even fewer with a viral load >50 copies/ml.

The COVID-19 landscape continues to change rapidly as new VOC are emerging. Recent studies have shown immune escape of the Omicron variant from humoral immunity induced by infection as well as vaccination [26]. However, at least in HIV-negative people, this can be overruled by a booster vaccination [21]. Additionally, higher antibody levels are associated with greater protection against symptomatic disease [29, 30]. This highlights the importance that additional vaccinations can play in controlling the pandemic. Based on the results of this study, we decided to give all participating PLWH with an antibody response below 300 BAU/ml the opportunity to receive an additional mRNA-1273 vaccination. Furthermore, given the safety of the mRNA vaccines, the overall lower vaccine inducible antibody response observed in PLWH, the observed waning of serum antibody levels over time, and immune escape by VOC, we think that providing additional vaccinations to all PLWH may optimise protection. An argument can be made for a more targeted approach in for example older PLWH, those with lower CD4+ T-cells, or based on measured antibody responses and neutralisation capacity after vaccination, however, we consider this too impractical.

395 In conclusion, vaccination against SARS-CoV-2 of PLWH resulted in a lower antibody response 396 compared to HIV-negative controls. Additional vaccinations may therefore be required in order to 397 compensate for this reduced antibody response.

### 398 Acknowledgements

399 Foremost, we would like to thank all participants of the study to help advancing science. We also want 400 to thank the following people who helped in the recruitment of participants: Aniek Adams, A. Boonstra, 401 Marjolein van Broekhuizen, Margo van der Burg-van der Plas, A. Cents-Bosma, Willemien Dorama, T. 402 Duijf, S. Faber, Natasja van Holten, Astrid van Hulzen, L.M. Kampschreur, Annemarie van der Kraan, 403 Inge de Kroon, Laura Laan, Eliane Leyten, Vera Maas, P.A. der Meulen, Femke Mollema, Suzanne de 404 Munnik, Hans-Erik Nobel, Vincent Peters, Simone Phaf, M. Pietersma, Frank Pijnappel, Leontine M.M. 405 van der Prijt, Linda Scheiberlich, Jasmijn Steiner, Jolanda M. van der Swaluw, Maartje Wagemaker, 406 Annouschka Weijsenveld, Marc van Wijk, Sieds Wildenbeest and Sabine van Winden. We would like to 407 thank all our colleague internist-infectious diseases specialists in the Netherlands who helped with the 408 patient recruitment. Finally, we would like to thank Alessandro Sette and Alba Grifoni (La Jolla Institute 409 for Immunology, La Jolla, San Diego, USA) for providing the peptide pools used in the AIM assay.

### 411 **References**

412 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of

413 the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.

- 414 2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
- 415 mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
- 416 3. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy
- 417 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
- 418 randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
- 419 4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety
- 420 and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young

421 and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet.

422 2021;396(10267):1979-93.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Final Analysis of
Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847-60.

425 6. Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al. Antibody

426 development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a

427 substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021.

428 7. Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Bene MC, et al. Safety and

429 Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic

430 Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2021;4(9):e2126344.

431 8. Carr EJ, Wu M, Harvey R, Wall EC, Kelly G, Hussain S, et al. Neutralising antibodies after

432 COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021;398(10305):1038-41.

- 433 9. Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS,
- 434 Dingemans AC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy,

435 immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-

436 inferiority trial. Lancet Oncol. 2021;22(12):1681-91.

437 10. Boffito M, Waters L. More evidence for worse COVID-19 outcomes in people with HIV. Lancet
438 HIV. 2021;8(11):e661-e2.

439 11. Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: A review. Hum
440 Vaccin Immunother. 2017;13(6):1-10.

441 12. Pallikkuth S, De Armas LR, Pahwa R, Rinaldi S, George VK, Sanchez CM, et al. Impact of aging

and HIV infection on serologic response to seasonal influenza vaccination. AIDS. 2018;32(9):1085-94.

443 13. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, et al. SARS-CoV-2

seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection,

445 compared by HIV status: a matched case-control observational study. Lancet HIV. 2021;8(6):e334-

446 e41.

14. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the

448 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a

449 phase 2/3 clinical trial. Lancet HIV. 2021.

450 15. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of

451 the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in

452 South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A

453 trial. Lancet HIV. 2021;8(9):e568-e80.

Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity
and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol
Infect. 2021.

457 17. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The
458 BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living
459 with HIV. Clin Infect Dis. 2021.

460 18. Heftdal LD, Knudsen AD, Hamm SR, Hansen CB, Moller DL, Pries-Heje M, et al. Humoral 461 response to two doses of BNT162b2 vaccination in people with HIV. J Intern Med. 2021. 462 19. Flemming A. Omicron, the great escape artist. Nat Rev Immunol. 2022;22(2):75. 463 20. van Sighem AI, Wit FWNM, Boyd A, Smit C, Matser A, Reiss P. Monitoring Report 2019. 464 Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Amsterdam: Stichting HIV 465 Monitoring; 2020. GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. Divergent 466 21. 467 SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 468 2022:eabo2202. 469 22. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. 470 Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus 471 disease-2019 (COVID-19). Nat Commun. 2021;12(1):267. 472 23. Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. 473 Cochrane Database Syst Rev. 2014(1):CD010929. 474 24. Ripa M, Chiappetta S, Tambussi G. Immunosenescence and hurdles in the clinical 475 management of older HIV-patients. Virulence. 2017;8(5):508-28. 476 25. Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune 477 response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417-22. 478 26. Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, et al. Vaccines Elicit 479 Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron. Nature. 2022. 480 27. Hoenigl M, Kessler HH, Gianella S. Editorial: HIV-Associated Immune Activation and Persistent 481 Inflammation. Front Immunol. 2019;10:2858. 482 28. Stichting HIV Monitoring. PRESS RELEASE: The Netherlands on course to reaching UNAIDS 483 2020 fast-track targets [updated 22 November 2018. Available from: https://www.hivmonitoring.nl/en/news/news-press-releases/press-release-hiv-diagnoses-continue-decline-484 485 netherlands-1.

- 486 29. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune
- 487 correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science.
- 488 2022;375(6576):43-50.
- 489 30. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
- 490 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
- 491 Nat Med. 2021;27(7):1205-11.

492

# 494 Supporting Information

#### 495 S1 Appendix

#### 496 Study Design and Participants

Inclusion was stratified according to vaccine type (mRNA, vector), sex assigned at birth, age (18-55, 56-65 and >65), and most recent CD4+ T-cell count (<350 and  $\geq$ 350 cells/µL). In order to recruit a study population that best represents the Dutch population of PLWH, we continuously monitored recruitment across these strata and strata were closed for enrolment when a sufficient number had been recruited [1].

502 All adult inhabitants of the Netherlands received an invitation for voluntary first round of vaccination 503 with either BNT162b2, mRNA-1273, ChAdOx1-S (AZD1222), or Ad26.COV2.S between January and 504 August 2021. The type of vaccination offered in the Netherlands was decided by the National Institute 505 for Public Health and the Environment and was dependent on vaccine availability, employment in 506 healthcare, age, and comorbidities. The government started vaccinating all healthcare workers and 507 people above 65 years old with BNT126b2 from the end of January 2021. Subsequently, from the 508 middle of February, all people between 60 and 64 years were invited for vaccination with ChAdOx1-S. 509 From March onwards, all people with a medical indication, which included PLWH, between 18 and 60 510 years old were invited for vaccination with either BNT162b2, ChAdOx1-S or mRNA-1273. However, on 511 the 8th of April the Governmental Dutch Health council suspended vaccination with ChAdOx1-S in 512 people under the age of 60 due to the possibility of blood clots with low levels of platelets. The interval 513 between the BNT162b2 vaccines was six weeks and between the mRNA-1273 vaccines five weeks. Up 514 to 20 May 2021 the interval between the ChAdOx1-S vaccines was 12 weeks, after which the interval 515 was changed to between four and 12 weeks. The Ad26.COV2.S vaccine was administered only once.

516 Vaccination response data from HIV-negative controls were obtained from two separate concurrent 517 studies. The first cohort consisted of health care workers from the Erasmus Medical Centre in

Rotterdam who were enrolled in a prospective cohort study (n=385). Health care workers received BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S according to national regulations as described above. The second group consisted of participants who served as non-immunocompromised controls in the Vaccination Against COVID-19 in Primary Immune Deficiencies (VACOPID) study investigating the mRNA-1273 vaccine in people with inborne errors of immunity (IEI) (n=55). They received two mRNA-1273 vaccines four weeks apart with blood sampling four weeks after the second vaccination. None of the controls had a history of COVID-19.

#### 525 Clinical Procedures

526 Study variables that were collected included year of birth, sex assigned at birth, current use of 527 combination antiretroviral therapy (cART), most recent plasma HIV-RNA (copies/mL), most recent 528 CD4+ T-cell count (cells/ $\mu$ L), and nadir CD4+ T-cell count (cells/ $\mu$ L).

#### 529 Laboratory Procedures

Serum samples before vaccination were analysed at the laboratory of the individual treating centres
using either Wantai SARS-CoV-2 total Ig and IgM ELISAs (Beijing Wantai Biological Pharmacy Enterprise
Co., Ltd. China), Abbott ARCHITECT SARS-CoV-2 IgG (Abbott Park, Illinois, U.S.A.), Siemens Atellica-IM
IgG (sCOVG) SARS-CoV-2 Serology Assay (Siemens Healthineers Nederland B.V.), or Liaison by DiaSorin
(Saluggia, Italy), depending on local availability and according to the manufacturer's instructions.

535 ELISpot assays were performed on cryopreserved PBMCs using a commercial double colour kit (Cellular 536 Technology Limited). ImmunoSpot plates were coated with capture antibodies and kept overnight at 537 4°C. The plates were washed one of the following overlapping peptide pools were added as stimuli to 538 the appropriate wells, with culture media (CTL-Test<sup>®</sup> medium with 1% L-Glutamine): spike 539 glycoprotein (S, PM-WCPV-S1), nucleocapsid (N) protein (PM-WCPV-NCAP-1), myelin-oligodendrocyte 540 glycoprotein (MOG) (PM-MOG, negative control), and CEFX (PM-CEFX-2, positive control) (all from 541 JPT) at a concentration of 2 μg/ml. PBMCs were plated at 200,000 cells per well and incubated 72 hours

(9% CO<sub>2</sub>). Cells were removed, detection antibodies and enzymes for visualisation of the cytokines
were added, after which plates were air dried in the dark prior to counting with the ImmunoSpot Image
Analyzer.

545 Activation induced marker (AIM) assays were also performed on cryopreserved PBMCs. 1x10<sup>6</sup> PBMCs 546 were incubated with SARS-CoV-2 peptide pools (1µg/mL) and incubated at 37°C for 20 hours. SARS-547 CoV-2 peptide pools consist of 15-mers with 10 amino acid overlaps covering the entire S-protein of 548 the WuhanHu1 (wild-type) (in PLWH) and D614G (wild-type) (in HIV-negative controls) or B.1.617.2 549 (delta) variant. PBMCs were stimulated with an equimolar amount DMSO as negative control or a 550 combination of PMA (50 µg/mL) and Ionomycin (500 µg/mL) as positive control. Following stimulation, 551 cells were stained and measured by flow cytometry (FACSLyric, BD). PBMC were stained at 4°C for 15 552 minutes with the following antibodies and dilutions: anti-CD3<sup>PerCP</sup> (Clone SK7, BD, 1:25), anti-CD4<sup>V50</sup> (Clone L200, BD, 1:50), anti-CD8<sup>FITC</sup> (Clone DK25, Dako, 1:25), anti-CD45RA<sup>PE-Cy7</sup> (Clone L48, BD, 1:50), 553 anti-CCR7<sup>BV711</sup>, anti-CD69<sup>APC-H7</sup> (Clone FN50, BD, 1:50), anti-CD137<sup>PE</sup> (Clone 4B4-1, Miltenyi, 1:50), and 554 anti-OX40<sup>BV605</sup> (Clone L106, BD, 1:25). LIVE/DEAD<sup>™</sup> Fixable Aqua Dead Cell staining was included 555 556 (AmCyan, Invitrogen, 1:100).

#### 557 Outcomes

Analysed variables associated with the height of antibody level; vaccine type (BNT162b2, mRNA-1273,
ChAdOx1-S, or Ad26.COV2.S), sex assigned at birth (male or female), age (birth year subgroups 19652002, 1964-1955 and <1954), nadir CD4+ T-cell count (<250, 250-500 and >500 cells/μL), and most
recent CD4+ T-cell count (<250, 250-500 and >500 cells/μL).

Analysed variables associated with hyporesponse and non-response; vaccine group (mRNA or vector),
sex at birth (male or female), age group (birth year subgroups 1965-2002, 1964-1955 and <1954), nadir</li>
CD4+ T-cell count (<250, 250-500 and >500 cells/μL), and most recent CD4+ T-cell count (<250, 250-500 and >500 cells/μL).

566	We evaluated the tolerability of the administered vaccines by monitoring local and systemic vaccine
567	related adverse events. Severity of reactogenicity was measured as mild (symptoms present but no
568	functional impairment or medication needed), moderate (necessitating medication, no functional
569	impairment) or severe (impairing in daily functioning). Severe adverse events (SAE) were assessed for
570	likeliness of association with vaccination by the participating site principal investigator and physician.

571

### 573 Supplementary References

- 1. van Sighem AI, Wit FWNM, Boyd A, Smit C, Matser A, Reiss P. Monitoring Report 2019. Human
- 575 Immunodeficiency Virus (HIV) Infection in the Netherlands. 2020. www.hiv-monitoring.nl.

**S1 Table: Baseline characteristics of HIV negative participants and PLWH per vaccine** 

		HIV negative participants						People living with HIV			
		Overall	BNT162b2	mRNA-	ChAdOx1-	Ad26.COV2.S	Overall	BNT162b2	mRNA-	ChAdOx1-S	Ad26.COV2.S
		N= 440	N= 94	1273	S	N=73 (16.6%)	N= 1154	N=884	1273	N=150	N=20 (1.7%)
			(21.4%)	N= 247	N= 26			(76.6%)	N= 100	(13.0%)	
				(56.1%)	(5.9%)				(8.7%)		
S	ex assigned at bi	rth					1				
	Male	126	31 (33%)	73	9 (34.6%)	13 (17.8%)	987 (85.5%)	751	88	133	15 (75.0%)
		(28.6%)		(29.6%)				(85.0%)	(88.0%)	(88.7%)	
	Female	314	63 (67.0%)	174	17	60 (82.2%)	167 (14.5%)	133	12	17 (11.3%)	5 (25.0%)
		(71.4%)		(70.4%)	(65.4%)			(15.0%)	(12.0%)		
A	ge category										
	18-55 yr.	352	81 (86.2%)	203	1 (3.8%)	67 (91.8%)	703 (60.9%)	590	84	12 (8.0%)	17 (85.0%)
		(80.0%)		(82.2%)				(66.7%)	(84.0%)		
	56-65 yr.	74 (16.8)	13 (13.8%)	30	25	9 (8.2%)	291 (25.2%)	141	16	131	3 (15.0%)
				(12.1%)	(96.2%)			(16.0%)	(16.0%)	(87.3%)	
	65+ yr.	14 (3.2%)	0	14 (5.7%)	0	0	160 (13.9%)	153	0	7 (4.7%)	0
								(17.3%)			
C	On Cart										
	Yes	NA	NA	NA	NA	NA	1142	873	99	150 (100%)	20 (100%)
							(99.0%)	(98.8%)	(99.0%)		
	No	NA	NA	NA	NA	NA	12 (1.0%)	11 (1.2%)	1 (1.0%)	0	0
Ν	/lost recent plasr	na HIV viral	load					-			
	<50	NA	NA	NA	NA	NA	1127	862	98	147	20 (100%)
	copies/mL						(97.7%)	(97.5%)	(98.0%)	(98.0%)	
	≥50	NA	NA	NA	NA	NA	26 (2.3%)	22 (2.5%)	2 (2.0%)	3 (2.0%)	0
	copies/mL										
Ν	/lost recent CD4+	T-cell coun	t								
	<250 cells/µL	NA	NA	NA	NA	NA	41 (3.6%)	32 (3.6%)	3 (3.0%)	5 (3.3%)	1 (5.0%)
	250-500	NA	NA	NA	NA	NA	224 (19.4%)	168	21	33 (22.0%)	2 (10.0%)
	cells/µL							(19.0%)	(21.0%)		
	>500 cells/µL	NA	NA	NA	NA	NA	889 (77.0%)	684	76	112	17 (85.0%)
								(77.4%)	(76.0%)	(74.7%)	
C	CD4 T-cell count nadir										

<250 cells/µ	L NA	NA	NA	NA	NA	443 (38.4%)	331	34	71 (47.3%)	7 (35.0%)
							(37.4%)	(34.0%)		
250-500	NA	NA	NA	NA	NA	376 (32.6%)	296	34	40 (26.7%)	6 (30.0%)
cells/µL							(33.5%)	(34.0%)		
>500 cells/µ	L NA	NA	NA	NA	NA	152 (13.2%)	114	19	17 (11.3%)	2 (10.0%)
							(12.9%)	(19.0%)		
Unknown	NA	NA	NA	NA	NA	183 (15.9%)	143	13	22 (14.7%)	5 (25.0%)
							(16.2%)	(13.0%)		
Days betwe	en 28 (25-	21 (21-23)	28 (28-	56 (56-70)	NA	35 (35-36)	35 (35-36)	35	71.5 (57-	NA
doses	28)		28)					(34.75-	77)	
								35)		
Hyporesponse	36 (8.2%)	0	0	0	36 (49.3%)	76 (6.5%)	42 (4.8%)	1 (1.0%)	22 (14.7%)	11 (57.9%)
(50-300										
BAU/mL)										
Nonresponse	46	0	0	10	36 (49.3%)	89 (7.7%)	17 (1.9%)	3 (3.0%)	60 (40.0%)	9 (42.1%)
(<50 BAU/mL)	(10.5%)			(38.5%)						

578 Data are n (%) or median (IQR). NA: not applicable, PLWH: people living with HIV, IQR: interquartile range, BAU/mL: binding antibodies per millilitre

### 579 S2 Table: Subgroup patient characteristics

	Serology	ELISpot*	AIM		
	People living	People living	People living	HIV negative	
	with HIV	with HIV	with HIV	participants	
	N=43	N=47	N=14	N=24	
Vaccine type		1	1	1	
BNT162b2	43 (95.3%)	31 (66.0%)	12 (85.7%)	5 (20.8%)	
mRNA-1273	0	4 (8.5%)	0	15 (62.5%)	
ChAdOx1-S	2 (4.7%)	12 (25.5%)	2 (14.3%)	4 (16.7%)	
Ad26.COV2.S	0	0	0	0	
Sex assigned at birth		1	1	1	
Male	52 (77.6%)	36 (76.6%)	12 (85.7%)	5 (20.8%)	
Female	15 (22.4%)	11 (23.4%)	2 (14.3%)	19 (79.2%)	
Age category	1	1	1	1	
18-55 yr.	31 (72.1%)	26 (55.3%)	7 (50.0%)	19 (79.2%)	
56-65 yr.	9 (20.9%)	17 (36.2%)	5 (35.7%)	5 (20.8%)	
65+ yr.	3 (7.0%)	4 (8.5%)	2 (14.3%)	0	
On cART	1			·	
Yes	42 (97.7%)	47 (100%)	14 (100%)	NA	
No	1 (2.3%)	0	0	NA	
Most recent plasma l	IV viral load			·	
<50 copies/mL	42 (97.7%)	47 (100%)	14 (100%)	NA	
≥50 copies/mL	1 (2.3%)	0	0	NA	
Most recent CD4+ T-c	ell count	·	·	·	
<250 cells/µL	3 (7.0%)	3 (6.4%)	3 (21.4%)	NA	
250-500 cells/μL	5 (11.6%)	6 (12.8%)	4 (28.6%)	NA	
>500 cells/µL	35 (81.4%)	38 (80.9%)	7 (50.0%)	NA	
CD4 T-cell count nadi	r				
<250 cells/µL	14 (32.6%)	18 (38.3%)	7 (50.0%)	NA	
250-500 cells/μL	15 (34.9%)	14 (29.8%)	3 (21.4%)	NA	
>500 cells/µL	7 (16.3%)	5 (10.6%)	1 (7.1%)	NA	
Unknown	7 (16.3%)	10 (21.3%)	3 (21.4%)	NA	

- 580 \*ELISpot: before vaccination n= 23, after vaccination n=45 Data are n (%)
- 581 NA: not applicable, IQR: interquartile range, ELISPot: enzyme-linked immune absorbent spot, AIM:
- 582 activation induced marker

### 584 S1 Fig: Gating strategy

- 585 Gating strategy for Flow Cytometry in AIM assay.
- 586 AIM: activation induced marker, MOG: myelin-oligodendrocyte glycoprotein



587

#### 589 S2 Fig: Serologic responses after vaccination in PLWH

590 T0: before vaccination, T1: 21 (+/-3) days after first vaccination, T2: 4-6 weeks after second vaccination

Antibody concentration measured as S-specific binding antibodies per millilitre (BAU/ml) in the subgroup participants (n=43) (T0 is Wantai, all negative). Green circles: PLWH who received mRNA vaccines, Blue squares: PLWH who received vector based vaccines. The dotted line shows the lower limit of detection (4.81 BAU/ml), statistics performed with Wilcoxon matched-pairs signed rank test (\*\*\*\* p<0.0001). S: spike, BAU/ml: binding antibodies per millilitre, PLWH: people living with HIV, LLOD: lower limit of detection



#### 598 S3 Fig: ELISPOT results in subgroup participants (PLWH)

- 599 T0: before vaccination, T2: 4-6 weeks after second vaccination
- 600 All ELISpot assay results shown as IFN-γ SFC. MOG: myelin-oligodendrocyte glycoprotein, SP1: spike
- 601 protein 1, SP2: spike protein 2, NC: nucleocapsid, PLWH: people living with HIV, IFN: interferon, SFC:
- 602 spot forming cells, PBMCs: peripheral blood mononuclear cells, ELISPot: enzyme-linked immune
- 603 absorbent spot

